What is Roivant Sciences' operating income?

Roivant Sciences' total operating income in 2025 was -$515.07 million, based on the following breakdown: Total Gross Profit: $8.26 million Total Operating Expenses: $523.33 million

Roivant Sciences (ROIV) Financials

$39.53 -0.46 (-1.15%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$39.68 +0.16 (+0.39%)

As of 11/13/2026 07:55 PM Eastern

Compare

Annual Income Statements for Roivant Sciences

This table shows Roivant Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-809	-845	-1,009	4,349	-172	-300
Consolidated Net Income / (Loss)	-900	-924	-1,115	4,231	-357	-398
Net Income / (Loss) Continuing Operations	-900	-924	-889	4,546	-730	-398
Total Pre-Tax Income	-899	-924	-885	4,568	-682	-265
Total Operating Income	-1,071	-1,352	-907	4,497	-1,003	-515
Total Gross Profit	24	55	32	33	29	8.26
Total Revenue	24	55	32	33	29	8.26
Operating Revenue	24	55	32	33	29	8.26
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	1,095	1,407	938	-4,464	1,032	523
Selling, General & Admin Expense	260	775	383	416	591	610
Research & Development Expense	833	623	552	466	550	682
Other Operating Expenses / (Income)	2.06	8.97	3.03	1.60	0.91	1.29
Other Special Charges / (Income)	-	-	0.00	-5,348	-110	-770
Total Other Income / (Expense), net	172	428	22	71	322	250
Interest & Investment Income	211	362	41	131	317	294
Other Income / (Expense), net	-39	73	-19	-60	5.04	-44
Income Tax Expense	1.69	0.37	4.08	22	48	133
Net Income / (Loss) Discontinued Operations	-	0.00	-226	-315	373	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-91	-79	-106	-118	-185	-98
Basic Earnings per Share	($1.28)	($1.26)	($1.42)	$5.55	($0.24)	($0.43)
Weighted Average Basic Shares Outstanding	630.05M	669.75M	712.79M	783.25M	725.40M	693.86M
Diluted Earnings per Share	($1.28)	($1.26)	($1.42)	$5.23	($0.24)	($0.54)
Weighted Average Diluted Shares Outstanding	630.05M	669.75M	712.79M	831.05M	725.40M	693.86M
Weighted Average Basic & Diluted Shares Outstanding	630.05M	669.75M	669.75M	738.72M	679.81M	719.27M

This table shows Roivant Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026	9/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-5,509	95	-230	169	-206	-223	-114	-266	303	-190	-192
Consolidated Net Income / (Loss)	-5,529	57	-280	118	-252	-274	-166	-314	356	-291	-137
Net Income / (Loss) Continuing Operations	-5,789	-32	-237	-209	-341	-274	-166	-314	356	-291	-153
Total Pre-Tax Income	-5,811	-20	-224	-235	-293	-269	-159	-290	454	-295	-166
Total Operating Income	-5,812	-102	-342	-274	-267	-285	-306	-339	415	-366	-268
Total Gross Profit	20	7.78	4.48	9.02	-40	2.17	1.46	2.00	2.67	1.44	32
Total Revenue	20	7.99	4.48	9.02	-40	2.17	1.57	2.00	2.52	1.44	35
Operating Revenue	20	7.99	4.48	9.02	-40	2.17	1.57	2.00	2.52	1.44	35
Total Cost of Revenue	-	0.21	0.00	0.00	-	0.00	0.11	0.00	-0.15	0.00	3.35
Operating Cost of Revenue	-	0.21	-	-	-	-	0.11	-	-	-	3.35
Total Operating Expenses	5,833	110	346	283	227	287	308	341	-413	367	300
Selling, General & Admin Expense	228	100	203	142	98	134	143	175	158	166	154
Research & Development Expense	248	121	143	142	133	153	165	165	199	202	146
Other Special Charges / (Income)	5,348	-110	0.00	0.00	-	0.00	0.00	0.00	-770	-0.39	0.00
Total Other Income / (Expense), net	1.59	83	117	40	-26	16	147	49	39	71	102
Interest & Investment Income	24	87	118	41	71	29	174	65	26	74	102
Other Income / (Expense), net	-3.56	-4.76	-0.82	-0.67	-110	-14	-27	-16	13	-2.13	-0.20
Income Tax Expense	-22	12	12	-26	49	4.65	7.00	23	98	-3.96	-13
Net Income / (Loss) Discontinued Operations	-	89	-43	327	-	-	0.00	0.00	-	-	16
Net Income / (Loss) Attributable to Noncontrolling Interest	-20	-38	-50	-51	-46	-51	-53	-48	53	-101	54
Basic Earnings per Share	($7.01)	$0.13	($0.31)	$0.23	($0.29)	($0.33)	($0.17)	($0.38)	$0.45	($0.26)	($0.27)
Weighted Average Basic Shares Outstanding	712.79M	735.82M	735.47M	722.72M	725.40M	680.29M	680.95M	696.86M	693.86M	720.78M	722.75M
Diluted Earnings per Share	($6.67)	$0.12	($0.31)	$0.23	($0.28)	($0.33)	($0.17)	($0.38)	$0.34	($0.26)	($0.27)
Weighted Average Diluted Shares Outstanding	712.79M	781.63M	735.47M	722.72M	725.40M	680.29M	680.95M	696.86M	693.86M	720.78M	722.75M
Weighted Average Basic & Diluted Shares Outstanding	738.72M	739.52M	727.95M	713.55M	679.81M	-	695.49M	715.70M	719.27M	722.32M	724.56M

This table details how cash moves in and out of Roivant Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Change in Cash & Equivalents	-128	-68	-382	4,858	-3,826	-1,298
Net Cash From Operating Activities	-552	-678	-843	-765	-839	-750
Net Cash From Continuing Operating Activities	-552	-678	-843	-765	-839	-750
Net Income / (Loss) Continuing Operations	-900	-924	-1,115	4,231	-357	-398
Consolidated Net Income / (Loss)	-900	-924	-1,115	4,231	-357	-398
Depreciation Expense	-	5.93	19	22	14	3.35
Amortization Expense	-	-	0.00	-	-70	-37
Non-Cash Adjustments To Reconcile Net Income	276	225	247	-5,038	-350	-468
Changes in Operating Assets and Liabilities, net	72	16	6.35	19	-77	148
Net Cash From Investing Activities	-32	303	-44	5,204	-1,766	-682
Net Cash From Continuing Investing Activities	-32	303	-44	5,204	-1,766	-682
Purchase of Property, Plant & Equipment	-5.81	-17	-13	-1.38	-4.60	-8.21
Acquisitions	-	-0.04	-6.71	-84	-31	-4.42
Purchase of Investments	-	-	0.00	0.00	-4,062	-4,796
Sale of Property, Plant & Equipment	-	-	0.00	5,233	110	0.00
Divestitures	-	-	0.00	48	261	0.00
Sale and/or Maturity of Investments	0.00	320	0.00	0.00	1,960	4,129
Other Investing Activities, net	-26	0.60	-25	8.59	0.08	-2.52
Net Cash From Financing Activities	456	307	499	419	-1,220	134
Net Cash From Continuing Financing Activities	456	307	499	419	-1,220	134
Repayment of Debt	0.00	-23	-30	-31	-53	0.00
Repurchase of Common Equity	-	-	0.00	0.00	-1,293	-320
Payment of Dividends	-	-	0.00	-6.00	0.00	0.00
Issuance of Common Equity	456	0.00	380	440	114	195
Other Financing Activities, net	0.51	294	-10	17	12	259
Cash Interest Paid	2.02	5.54	5.30	10	5.96	0.00

This table details how cash moves in and out of Roivant Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026	9/30/2026
Net Change in Cash & Equivalents	-5,375	-857	-3,664	-27	724	-1,477	-1.45	242	-62	-245	316
Net Cash From Operating Activities	-187	-193	-267	-207	-173	-204	-186	-196	-164	-271	594
Net Cash From Continuing Operating Activities	-187	-193	-267	-207	-173	-275	-186	-196	-164	-345	523
Net Income / (Loss) Continuing Operations	-5,529	57	-280	118	-252	-274	-166	-314	356	-291	-137
Consolidated Net Income / (Loss)	-5,529	57	-280	118	-252	-274	-166	-314	356	-291	-137
Depreciation Expense	2.05	4.88	4.84	2.92	1.43	1.10	0.92	0.69	0.64	0.60	0.60
Amortization Expense	-	0.00	-	-29	-16	-11	-9.82	-8.72	-6.91	-5.69	-4.92
Non-Cash Adjustments To Reconcile Net Income	5,337	-186	23	-246	60	46	-18	116	-682	-18	709
Changes in Operating Assets and Liabilities, net	3.27	-69	10	-53	34	-37	7.08	9.37	169	-31	-44
Net Cash From Investing Activities	-5,241	-0.97	-3,294	454	1,074	-1,086	120	109	173	281	43
Net Cash From Continuing Investing Activities	-5,241	-0.97	-3,294	454	1,074	-1,086	120	109	173	281	43
Purchase of Property, Plant & Equipment	-12	-0.97	-1.00	-1.83	-0.81	-4.04	-7.85	4.94	-1.26	-0.42	-0.21
Purchase of Investments	-	0.00	-	-659	-	-1,802	-977	-1,014	-1,004	-287	-832
Sale and/or Maturity of Investments	-	0.00	-	-	1,000	720	1,105	1,121	1,183	568	856
Net Cash From Financing Activities	47	-661	-109	-273	-177	-188	63	328	-69	-182	-249
Net Cash From Continuing Financing Activities	47	-661	-109	-273	-177	-188	63	328	-69	-182	-249
Repurchase of Common Equity	-	-648	-106	-243	-295	-208	-	-	-111	-207	-74
Other Financing Activities, net	-52	-10	-1.84	19	5.13	21	62	134	42	25	-175

This table presents Roivant Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Total Assets	2,590	2,585	2,390	7,222	5,437	5,709
Total Current Assets	2,187	2,147	1,799	6,732	5,000	5,167
Cash & Equivalents	2,055	2,060	1,677	6,495	2,715	1,419
Short-Term Investments	-	-	-	0.00	2,171	2,873
Other Current Assets	54	86	122	81	113	876
Plant, Property, & Equipment, net	15	26	39	15	12	12
Total Noncurrent Assets	388	413	552	475	425	529
Long-Term Investments	290	326	304	248	303	408
Other Noncurrent Operating Assets	98	87	103	82	122	121
Total Liabilities & Shareholders' Equity	2,590	2,585	2,390	7,222	5,437	5,709
Total Liabilities	528	524	782	774	250	416
Total Current Liabilities	219	184	272	267	149	281
Accounts Payable	21	35	38	14	24	18
Accrued Expenses	77	128	167	119	114	206
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	0.42	46
Other Current Liabilities	116	22	27	23	11	12
Total Noncurrent Liabilities	309	339	510	507	100	135
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	0.00	39
Other Noncurrent Operating Liabilities	138	129	134	73	100	96
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,040	2,039	1,608	6,449	5,187	5,292
Total Preferred & Common Equity	1,798	1,657	1,158	5,969	4,688	4,527
Total Common Equity	1,798	1,657	1,158	5,969	4,688	4,527
Common Stock	3,815	4,422	4,933	5,396	4,562	5,025
Retained Earnings	-1,918	-2,764	-3,773	576	116	-502
Accumulated Other Comprehensive Income / (Loss)	1.45	-0.95	-2.62	-4.08	9.44	4.36
Noncontrolling Interest	242	382	450	480	500	765

This table presents Roivant Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024	12/31/2024	6/30/2025	9/30/2025	12/31/2025	6/30/2026	9/30/2026
Total Assets	2,137	2,066	7,313	6,496	6,206	5,792	5,033	5,063	5,225	5,306	4,976
Total Current Assets	1,561	1,552	6,807	6,001	5,801	5,364	4,616	4,512	4,660	4,742	4,356
Cash & Equivalents	1,434	1,408	6,671	5,679	1,959	1,991	1,238	1,237	1,478	1,248	1,642
Short-Term Investments	-	-	-	-	3,428	3,156	3,265	3,149	3,052	2,594	2,565
Other Current Assets	127	143	136	323	94	217	113	126	130	900	148
Plant, Property, & Equipment, net	36	24	22	18	14	14	15	26	13	11	11
Total Noncurrent Assets	539	489	484	477	391	415	402	525	552	553	609
Long-Term Investments	296	250	240	263	311	290	284	412	434	445	505
Other Noncurrent Operating Assets	98	98	94	78	80	125	118	113	118	108	104
Total Liabilities & Shareholders' Equity	2,137	2,066	7,313	6,496	6,206	5,792	5,033	5,063	5,225	5,306	4,976
Total Liabilities	803	740	728	601	626	256	217	257	251	385	380
Total Current Liabilities	245	266	245	215	556	141	114	134	152	284	280
Accounts Payable	50	44	35	28	25	24	12	15	13	25	11
Accrued Expenses	119	153	122	138	111	104	89	108	118	169	188
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	-	-	74	59
Other Current Liabilities	31	20	42	37	18	13	14	10	21	16	22
Total Noncurrent Liabilities	558	474	483	386	70	115	103	123	99	101	100
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	-	-	0.00	0.00
Other Noncurrent Operating Liabilities	172	85	80	74	70	115	103	123	99	101	100
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,334	1,326	6,585	5,895	5,580	5,536	4,816	4,805	4,974	4,922	4,596
Total Preferred & Common Equity	911	949	6,090	5,435	5,153	5,189	4,346	4,362	4,269	4,231	4,020
Total Common Equity	911	949	6,090	5,435	5,153	5,189	4,346	4,362	4,269	4,231	4,020
Common Stock	4,982	5,321	5,390	4,782	4,775	4,721	4,644	4,772	4,944	5,131	5,194
Retained Earnings	-4,065	-4,369	727	671	396	460	-316	-429	-695	-900	-1,164
Accumulated Other Comprehensive Income / (Loss)	-6.61	-3.07	-28	-18	-18	8.06	17	20	21	0.70	-8.93
Noncontrolling Interest	423	377	495	460	427	346	470	443	705	691	575

This table displays calculated financial ratios and metrics derived from Roivant Sciences' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2021	3/31/2021	3/31/2022	3/31/2024	3/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	715,701,137.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	715,701,137.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-0.42
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	132.34%	125.73%	-11.19%	-71.57%
EBITDA Growth	0.00%	0.00%	-14.71%	428.12%	-123.64%	43.85%
EBIT Growth	0.00%	0.00%	-15.25%	425.13%	-122.50%	44.03%
NOPAT Growth	0.00%	0.00%	-26.22%	546.00%	-115.69%	48.66%
Net Income Growth	0.00%	0.00%	-2.65%	557.87%	-108.43%	-11.54%
EPS Growth	0.00%	0.00%	1.56%	515.08%	-104.59%	-125.00%
Operating Cash Flow Growth	0.00%	0.00%	-22.75%	-24.44%	-9.69%	10.61%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	507.01%	-117.03%	-27.16%
Invested Capital Growth	0.00%	0.00%	39.59%	54.72%	94.94%	22,614.97%
Revenue Q/Q Growth	0.00%	0.00%	375.13%	6.44%	-67.38%	-37.94%
EBITDA Q/Q Growth	0.00%	0.00%	-19.17%	-0.75%	83.59%	54.52%
EBIT Q/Q Growth	0.00%	0.00%	-19.73%	-0.97%	84.49%	55.66%
NOPAT Q/Q Growth	0.00%	0.00%	-45.78%	3.50%	84.68%	57.62%
Net Income Q/Q Growth	0.00%	0.00%	30.10%	-6.89%	93.67%	60.45%
EPS Q/Q Growth	0.00%	0.00%	30.39%	-2.79%	96.38%	53.45%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	1.23%	-25.84%	1.64%	1.15%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-22.87%	4.07%	83.52%	-25.49%
Invested Capital Q/Q Growth	0.00%	-33.67%	-386.36%	-142.29%	-102.65%	5,631.64%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-4,662.51%	-4,662.51%	-2,301.93%	3,346.16%	-3,628.36%	-7,166.15%
Operating Margin	-4,500.52%	-4,500.52%	-2,444.82%	3,399.19%	-3,453.32%	-6,235.69%
EBIT Margin	-4,662.51%	-4,662.51%	-2,312.66%	3,331.05%	-3,435.99%	-6,764.65%
Profit (Net Income) Margin	-3,783.29%	-3,783.29%	-1,671.52%	3,390.53%	-1,227.87%	-4,817.28%
Tax Burden Percent	100.19%	100.19%	100.04%	99.48%	52.34%	150.39%
Interest Burden Percent	80.99%	80.99%	72.25%	102.32%	68.28%	47.35%
Effective Tax Rate	0.00%	0.00%	0.00%	0.52%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-122.23%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-121.47%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	114.63%
Return on Equity (ROE)	-43.66%	-43.66%	-44.82%	99.44%	-6.13%	-7.59%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-161.29%
Operating Return on Assets (OROA)	-42.84%	-42.84%	-49.42%	84.77%	-15.77%	-10.03%
Return on Assets (ROA)	-34.76%	-34.76%	-35.72%	86.28%	-5.64%	-7.14%
Return on Common Equity (ROCE)	-38.06%	-38.06%	-37.55%	89.11%	-5.62%	-6.68%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-50.07%	-55.77%	70.89%	-7.61%	0.00%
Net Operating Profit after Tax (NOPAT)	-750	-750	-946	4,220	-702	-361
NOPAT Margin	-3,150.36%	-3,150.36%	-1,711.37%	3,381.43%	-2,417.33%	-4,364.98%
Net Nonoperating Expense Percent (NNEP)	-6.69%	-6.69%	1.00%	0.26%	5.91%	-0.76%
Return On Investment Capital (ROIC_SIMPLE)	-33.92%	-	-	-	-13.54%	-6.81%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,092.15%	1,092.15%	1,401.86%	550.86%	2,035.62%	7,390.63%
R&D to Revenue	3,499.72%	3,499.72%	1,126.74%	423.24%	1,894.51%	8,254.38%
Operating Expenses to Revenue	4,600.52%	4,600.52%	2,544.82%	-3,299.19%	3,553.32%	6,335.69%
Earnings before Interest and Taxes (EBIT)	-1,109	-1,109	-1,279	4,157	-998	-559
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1,109	-1,109	-1,273	4,176	-1,054	-592
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	2.06	1.42	1.54	4.38
Price to Tangible Book Value (P/TBV)	0.00	0.00	2.06	1.42	1.54	4.38
Price to Revenue (P/Rev)	0.00	0.00	61.84	68.06	247.81	2,400.11
Price to Earnings (P/E)	0.00	0.00	0.00	1.95	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	51.20%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	26.81
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	29.79	17.88	86.38	1,923.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.53	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.54	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.53	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.54	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.08	0.08	0.10	0.00	0.00	0.00
Long-Term Debt to Equity	0.08	0.08	0.10	0.00	0.00	0.00
Financial Leverage	-1.09	-1.09	-1.07	-1.02	-1.00	-0.94
Leverage Ratio	1.26	1.26	1.26	1.15	1.09	1.06
Compound Leverage Factor	1.02	1.02	0.91	1.18	0.74	0.50
Debt to Total Capital	7.63%	7.63%	9.25%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	7.63%	7.63%	9.25%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	11.84%	11.84%	17.81%	7.44%	9.63%	14.46%
Common Equity to Total Capital	80.54%	80.54%	72.95%	92.56%	90.37%	85.54%
Debt to EBITDA	-0.15	-0.15	-0.17	0.00	0.00	0.00
Net Debt to EBITDA	2.03	2.03	1.71	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.15	-0.15	-0.17	0.00	0.00	0.00
Debt to NOPAT	-0.23	-0.23	-0.22	0.00	0.00	0.00
Net Debt to NOPAT	3.00	3.00	2.30	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.23	-0.23	-0.22	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	1.72	9.69	17.80	29.16
Noncontrolling Interest Sharing Ratio	12.81%	12.81%	16.22%	10.39%	8.42%	12.07%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	9.99	9.99	11.64	25.24	33.47	18.37
Quick Ratio	9.39	9.39	11.18	24.35	32.71	15.26
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	-1,021	4,157	-752	-956
Operating Cash Flow to CapEx	-9,509.78%	-9,509.78%	-3,886.95%	-6,646.12%	0.00%	-9,140.57%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-145.06	119.53	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-96.25	-24.25	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-98.73	-24.62	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.01	0.01	0.02	0.03	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.61	1.61	2.72	6.05	2.12	0.69
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-190	-190	-115	-52	-2.63	593
Invested Capital Turnover	-0.13	-0.13	-0.36	-1.50	-1.06	0.03
Increase / (Decrease) in Invested Capital	0.00	0.00	75	63	49	595
Enterprise Value (EV)	0.00	0.00	1,647	2,231	2,509	15,890
Market Capitalization	0.00	0.00	3,419	8,494	7,200	19,825
Book Value per Share	$2.85	$2.85	$2.39	$7.41	$6.57	$6.33
Tangible Book Value per Share	$2.85	$2.85	$2.39	$7.41	$6.57	$6.33
Total Capital	2,232	2,232	2,271	6,449	5,187	5,292
Total Debt	170	170	210	0.00	0.00	0.00
Total Long-Term Debt	170	170	210	0.00	0.00	0.00
Net Debt	-2,252	-2,252	-2,176	-6,743	-5,190	-4,700
Capital Expenditures (CapEx)	5.81	5.81	17	13	-106	8.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-165	-165	-98	-30	-36	594
Debt-free Net Working Capital (DFNWC)	1,968	1,968	1,962	6,465	4,851	4,886
Net Working Capital (NWC)	1,968	1,968	1,962	6,465	4,851	4,886
Net Nonoperating Expense (NNE)	151	151	-22	-11	-346	37
Net Nonoperating Obligations (NNO)	-2,252	-2,252	-2,176	-6,501	-5,190	-4,700
Total Depreciation and Amortization (D&A)	0.00	0.00	5.93	19	-56	-33
Debt-free, Cash-free Net Working Capital to Revenue	-692.21%	-692.21%	-177.70%	-23.95%	-124.73%	7,195.00%
Debt-free Net Working Capital to Revenue	8,270.79%	8,270.79%	3,549.10%	5,180.55%	16,695.88%	59,154.24%
Net Working Capital to Revenue	8,270.79%	8,270.79%	3,549.10%	5,180.55%	16,695.88%	59,154.24%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.26)	$5.55	($0.24)	($0.43)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	700.77M	783.25M	725.40M	693.86M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.26)	$5.23	($0.24)	($0.54)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	700.77M	831.05M	725.40M	693.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($1.26)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	669.75M	738.72M	679.81M	719.27M
Normalized Net Operating Profit after Tax (NOPAT)	-750	-750	-946	-1,101	-780	-900
Normalized NOPAT Margin	-3,150.36%	-3,150.36%	-1,711.37%	-881.94%	-2,683.29%	-10,892.40%
Pre Tax Income Margin	-3,776.20%	-3,776.20%	-1,670.85%	3,408.33%	-2,346.02%	-3,203.12%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-181.59	119.53	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	-134.38	121.34	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-184.07	119.16	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-136.85	120.97	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-362.52%	-80.30%

This table displays calculated financial ratios and metrics derived from Roivant Sciences' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026	9/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	715,701,137.00	719,270,385.00	722,323,015.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	715,701,137.00	719,270,385.00	722,323,015.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	0.42	-0.26	-0.27
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-4.38%	154.96%	22.67%	-42.05%	-387.28%	-72.84%	-64.89%	-77.83%	-66.71%	-33.55%	2,135.58%
EBITDA Growth	-2,090.43%	100.34%	-52.37%	-105.87%	-186.18%	-202.05%	5.77%	-20.53%	246.41%	-21.01%	20.25%
EBIT Growth	-2,150.31%	98.83%	-50.76%	-105.36%	-165.62%	-178.95%	2.82%	-29.15%	256.32%	-23.34%	19.42%
NOPAT Growth	-825.75%	49.09%	-59.76%	-103.76%	-90.56%	-178.69%	10.38%	-23.61%	263.08%	-28.45%	12.47%
Net Income Growth	-4,337.40%	117.54%	15.46%	-97.67%	-38.29%	-576.45%	40.68%	-365.68%	240.96%	-6.10%	17.36%
EPS Growth	0.00%	131.58%	22.50%	-96.19%	-1,300.00%	-375.00%	45.16%	-265.22%	221.43%	21.21%	-58.82%
Operating Cash Flow Growth	-1,289.91%	22.85%	-35.83%	1.52%	-59.11%	-5.99%	30.41%	5.20%	5.07%	-32.35%	420.16%
Free Cash Flow Firm Growth	-702.66%	-22.70%	45.90%	-103.36%	-46.84%	115.56%	-167.34%	12.03%	-8.48%	-1,855.65%	75.43%
Invested Capital Growth	54.72%	733.91%	-135.08%	-19.10%	94.94%	-89.57%	119.76%	-89.60%	22,614.97%	2,094.69%	-1,697.97%
Revenue Q/Q Growth	31.38%	90.57%	-91.88%	101.52%	-538.81%	105.48%	-27.60%	27.24%	26.06%	-42.78%	2,335.58%
EBITDA Q/Q Growth	-213.17%	100.37%	-31,542.18%	10.75%	-29.76%	21.14%	-10.82%	-6.28%	216.05%	-188.54%	26.97%
EBIT Q/Q Growth	-213.33%	98.73%	-8,892.68%	19.70%	-37.02%	20.81%	-11.53%	-6.71%	220.43%	-186.05%	27.13%
NOPAT Q/Q Growth	-179.70%	47.10%	-142.83%	19.70%	2.69%	-6.71%	-7.48%	-10.75%	237.02%	-178.76%	26.76%
Net Income Q/Q Growth	-209.00%	131.50%	-586.91%	142.18%	-313.74%	-8.53%	39.38%	-88.93%	213.40%	-181.69%	52.78%
EPS Q/Q Growth	0.00%	700.00%	-358.33%	174.19%	-221.74%	-17.86%	48.48%	-123.53%	189.47%	-176.47%	-3.85%
Operating Cash Flow Q/Q Growth	11.34%	-77.79%	-38.36%	22.32%	16.74%	-18.44%	9.16%	-5.83%	16.63%	-65.12%	319.74%
Free Cash Flow Firm Q/Q Growth	-182.26%	16.13%	71.77%	-74.26%	-40.12%	120.79%	-626.57%	42.66%	-81.98%	-219.51%	92.63%
Invested Capital Q/Q Growth	-142.29%	157.76%	-113.33%	368.77%	-102.65%	1,199.58%	-74.75%	41.48%	5,631.64%	7.18%	-118.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	0.00%	92.90%	100.00%	100.00%	106.11%	100.00%	90.47%
EBITDA Margin	-28,435.79%	1.95%	-7,546.12%	-3,342.17%	0.00%	-14,213.00%	-21,756.02%	-18,172.04%	16,727.94%	-25,881.69%	-776.07%
Operating Margin	-28,428.39%	-218.00%	-7,636.04%	-3,042.59%	0.00%	-13,130.05%	-19,492.87%	-16,966.13%	16,477.78%	-25,380.93%	-763.22%
EBIT Margin	-28,445.80%	-6.91%	-7,654.32%	-3,050.01%	0.00%	-13,753.87%	-21,189.43%	-17,770.24%	16,976.67%	-25,528.64%	-763.79%
Profit (Net Income) Margin	-27,042.77%	104.28%	-6,255.28%	1,309.33%	0.00%	-12,622.63%	-10,569.00%	-15,692.90%	14,116.83%	-20,152.98%	-390.68%
Tax Burden Percent	95.15%	81.96%	124.75%	-50.35%	86.18%	101.73%	104.40%	108.04%	78.34%	98.66%	82.49%
Interest Burden Percent	99.91%	-1,841.56%	65.51%	85.26%	77.70%	90.22%	47.78%	81.74%	106.14%	80.02%	62.01%
Effective Tax Rate	0.00%	18.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	21.66%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-182.01%	-24,849.16%	-1,706.67%	0.00%	-1,393.61%	0.00%	-2,880.32%	361.47%	-403.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-186.52%	-24,847.97%	-1,711.88%	0.00%	-1,392.17%	0.00%	-2,878.85%	360.86%	-402.24%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	178.50%	24,601.63%	1,680.48%	0.00%	1,352.34%	0.00%	2,848.79%	-340.54%	374.81%	0.00%
Return on Equity (ROE)	99.44%	-3.51%	-247.52%	-26.19%	-6.13%	-41.26%	-11.06%	-31.53%	20.93%	-28.19%	-8.21%
Cash Return on Invested Capital (CROIC)	0.00%	2,653.06%	0.00%	-4,102.97%	0.00%	-379.58%	-11,626.31%	-1,387.76%	-161.29%	-308.24%	0.00%
Operating Return on Assets (OROA)	-723.91%	-0.25%	-294.51%	-41.46%	0.00%	-55.43%	-76.45%	-42.93%	25.16%	-37.20%	-6.25%
Return on Assets (ROA)	-688.20%	3.82%	-240.68%	17.80%	0.00%	-50.87%	-38.13%	-37.92%	20.92%	-29.36%	-3.20%
Return on Common Equity (ROCE)	89.11%	-3.08%	-218.70%	-24.37%	-5.62%	-37.68%	-10.13%	-28.38%	18.40%	-24.83%	-7.32%
Return on Equity Simple (ROE_SIMPLE)	0.00%	84.94%	90.58%	-108.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4,069	-99	-239	-192	-187	-199	-214	-237	325	-256	-188
NOPAT Margin	-19,899.87%	-178.67%	-5,345.23%	-2,129.81%	0.00%	-9,191.03%	-13,645.01%	-11,876.29%	12,908.85%	-17,766.65%	-534.25%
Net Nonoperating Expense Percent (NNEP)	-33.66%	4.51%	-1.19%	5.21%	-1.12%	-1.43%	0.93%	-1.47%	0.62%	-0.76%	1.06%
Return On Investment Capital (ROIC_SIMPLE)	-63.10%	-	-	-3.47%	-3.60%	-4.14%	-4.46%	-4.77%	6.15%	-5.21%	-4.08%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	7.10%	0.00%	0.00%	-6.11%	0.00%	9.53%
SG&A Expenses to Revenue	1,113.02%	269.39%	4,533.65%	1,569.58%	0.00%	6,175.99%	9,110.44%	8,757.98%	6,279.76%	11,478.99%	438.70%
R&D to Revenue	1,215.12%	241.62%	3,197.16%	1,570.14%	0.00%	7,046.96%	10,475.37%	8,273.14%	7,894.64%	14,009.43%	414.99%
Operating Expenses to Revenue	28,528.39%	318.00%	7,736.04%	3,142.59%	0.00%	13,222.95%	19,592.87%	17,066.13%	-16,371.67%	25,480.93%	853.69%
Earnings before Interest and Taxes (EBIT)	-5,816	-3.81	-343	-275	-377	-298	-333	-355	428	-368	-268
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5,814	1.07	-338	-301	-391	-308	-342	-363	422	-373	-273
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.94	1.44	1.66	1.66	1.54	1.76	2.36	3.54	4.38	6.02	6.57
Price to Tangible Book Value (P/TBV)	0.94	1.47	1.66	1.66	1.54	1.76	2.36	3.54	4.38	6.02	6.57
Price to Revenue (P/Rev)	44.85	49.33	53.63	96.68	247.81	329.76	505.95	1,133.90	2,400.11	3,379.58	642.99
Price to Earnings (P/E)	1.29	1.65	1.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	77.70%	60.65%	56.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	9.55	0.00	35.42	0.00	115.57	811.50	1,047.80	26.81	34.41	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	16.74	20.51	39.54	86.38	143.96	291.72	813.92	1,923.75	2,902.13	542.29
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.59	0.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.59	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.61	0.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.64	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-0.96	-0.99	-0.98	-1.00	-0.97	-1.00	-0.99	-0.94	-0.93	-1.01
Leverage Ratio	1.15	1.19	1.20	1.08	1.09	1.08	1.09	1.05	1.06	1.06	1.07
Compound Leverage Factor	1.15	-21.99	0.78	0.92	0.85	0.97	0.52	0.86	1.13	0.85	0.66
Debt to Total Capital	0.00%	5.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	5.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	7.44%	7.40%	7.65%	6.26%	9.63%	9.77%	9.22%	14.17%	14.46%	14.03%	12.52%
Common Equity to Total Capital	92.56%	87.40%	92.35%	93.74%	90.37%	90.24%	90.78%	85.83%	85.54%	85.97%	87.48%
Debt to EBITDA	0.00	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	-1.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	-1.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.88	9.03	9.13	21.21	18.17	22.01	24.71	36.68	29.73	40.25	42.18
Noncontrolling Interest Sharing Ratio	10.39%	12.22%	11.65%	6.94%	8.42%	8.68%	8.38%	10.00%	12.07%	11.92%	10.83%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	25.24	27.91	10.43	37.91	33.47	40.54	33.71	30.66	18.37	16.72	15.56
Quick Ratio	24.35	26.41	9.68	36.38	32.71	39.55	32.77	29.81	15.26	13.55	15.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4,132	-343	-97	-169	-236	49	-259	-148	-270	-862	-64
Operating Cash Flow to CapEx	-3.56%	-19,982.28%	-26,787.75%	-11,343.79%	-21,278.05%	-5,065.25%	-2,365.75%	0.00%	-12,991.12%	-64,559.43%	285,777.88%
Free Cash Flow to Firm to Interest Expense	0.00	-25.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-14.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-14.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.03	0.04	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	6.05	5.85	8.34	5.03	2.12	1.42	1.03	0.99	0.69	0.58	2.24
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,487.07
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1,487.07
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-52	278	-37	99	-2.63	29	7.31	10	593	635	-117
Invested Capital Turnover	-1.50	1.02	4.65	0.80	-1.06	0.15	-1.37	0.24	0.03	0.02	-0.75
Increase / (Decrease) in Invested Capital	63	244	-142	-23	49	-249	44	-89	595	606	-124
Enterprise Value (EV)	-666	2,650	3,263	3,522	2,509	3,345	5,930	10,833	15,890	21,859	22,278
Market Capitalization	5,597	7,808	8,534	8,612	7,200	7,661	10,285	15,092	19,825	25,455	26,415
Book Value per Share	$7.41	$7.36	$6.97	$7.13	$6.57	$6.39	$6.41	$6.14	$6.33	$5.88	$5.57
Tangible Book Value per Share	$7.41	$7.17	$6.97	$7.13	$6.57	$6.39	$6.41	$6.14	$6.33	$5.88	$5.57
Total Capital	6,449	6,219	5,580	5,536	5,187	4,816	4,805	4,974	5,292	4,922	4,596
Total Debt	0.00	324	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	312	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-6,743	-5,618	-5,698	-5,437	-5,190	-4,787	-4,798	-4,964	-4,700	-4,287	-4,713
Capital Expenditures (CapEx)	5,245	0.97	1.00	1.83	0.81	4.04	7.85	-4.94	1.26	0.42	0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-30	120	-142	76	-36	-1.27	-8.05	-22	594	616	-132
Debt-free Net Working Capital (DFNWC)	6,465	5,798	5,245	5,222	4,851	4,502	4,378	4,508	4,886	4,458	4,076
Net Working Capital (NWC)	6,465	5,786	5,245	5,222	4,851	4,502	4,378	4,508	4,886	4,458	4,076
Net Nonoperating Expense (NNE)	1,460	-156	41	-310	65	74	-48	76	-30	34	-50
Net Nonoperating Obligations (NNO)	-6,501	-5,618	-5,617	-5,437	-5,190	-4,787	-4,798	-4,964	-4,700	-4,287	-4,713
Total Depreciation and Amortization (D&A)	2.05	4.88	4.84	-26	-14	-9.96	-8.90	-8.03	-6.27	-5.09	-4.32
Debt-free, Cash-free Net Working Capital to Revenue	-23.95%	75.77%	-89.10%	85.30%	-124.73%	-5.45%	-39.58%	-165.68%	7,195.00%	8,183.68%	-321.20%
Debt-free Net Working Capital to Revenue	5,180.55%	3,662.88%	3,295.97%	5,863.28%	16,695.88%	19,377.11%	21,534.70%	33,868.72%	59,154.24%	59,193.80%	9,920.72%
Net Working Capital to Revenue	5,180.55%	3,655.30%	3,295.97%	5,863.28%	16,695.88%	19,377.11%	21,534.70%	33,868.72%	59,154.24%	59,193.80%	9,920.72%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($7.01)	$0.13	($0.31)	$0.23	($0.29)	($0.33)	($0.17)	($0.38)	$0.45	($0.26)	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	712.79M	735.82M	735.47M	722.72M	725.40M	680.29M	680.95M	696.86M	693.86M	720.78M	722.75M
Adjusted Diluted Earnings per Share	($6.67)	$0.12	($0.31)	$0.23	($0.28)	($0.33)	($0.17)	($0.38)	$0.34	($0.26)	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	712.79M	781.63M	735.47M	722.72M	725.40M	680.29M	680.95M	696.86M	693.86M	720.78M	722.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	738.72M	739.52M	727.95M	713.55M	679.81M	0.00	695.49M	715.70M	719.27M	722.32M	724.56M
Normalized Net Operating Profit after Tax (NOPAT)	-325	-189	-239	-192	-187	-199	-214	-237	-278	-256	-188
Normalized NOPAT Margin	-1,588.78%	-342.77%	-5,345.23%	-2,129.81%	0.00%	-9,191.03%	-13,645.01%	-11,876.29%	-11,035.97%	-17,785.68%	-534.25%
Pre Tax Income Margin	-28,420.62%	127.23%	-5,014.15%	-2,600.50%	0.00%	-12,408.39%	-10,123.74%	-14,525.71%	18,019.72%	-20,427.46%	-473.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-0.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-7.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-7.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	-0.13%	0.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.13%	0.11%	-362.52%	-123.98%	-130.10%	-50.07%	-80.30%	-76.69%	-101.72%

Financials Breakdown Chart

Key Financial Trends

Roivant Sciences’ latest quarter shows a company with a substantial liquidity cushion but continued operating losses. As of June 30, 2026, Roivant held $1.25 billion in cash and equivalents, $2.59 billion in short-term investments and $444.6 million in long-term investments. Combined, these assets totaled approximately $4.29 billion, or about 81% of total assets.

The balance sheet remains lightly levered. Total liabilities were just $384.6 million against $5.31 billion of assets, and the company reported no short-term or long-term debt in the latest statement. This produced a current ratio of roughly 16.7, providing meaningful financial flexibility. However, liquid assets have declined from the elevated levels reported in 2023 and 2024, while retained earnings have deteriorated to a deficit of $900.4 million.

Roivant’s operating business is not yet self-funding. Q1 2026 revenue was only $1.4 million, down from $2.5 million in the prior quarter and $2.2 million in the year-ago quarter. Against that revenue, the company incurred $165.5 million of selling, general and administrative expense and $202.0 million of research and development expense. The resulting operating loss was $366.0 million. Interest and investment income of $73.6 million reduced the net loss, but consolidated net loss still totaled $290.6 million, or $0.26 per share.

Cash flow trends remain a key concern. Operating cash flow was negative $270.5 million in Q1 2026, compared with negative $163.8 million in Q4 2025 and negative $204.4 million in Q1 2025. Roivant offset part of this burn through investment sales and maturities, which generated $568.2 million during the quarter. Financing cash flow was negative $181.5 million, primarily reflecting a $206.7 million share repurchase.

Large liquidity reserve: Cash, short-term investments and long-term investments totaled approximately $4.29 billion at the end of Q1 2026.
Low balance-sheet leverage: Total liabilities were only $384.6 million, with no reported short-term or long-term debt in the latest quarter.
Investment income provides support: Interest and investment income increased to $73.6 million in Q1 2026 from $26.3 million in Q4 2025, helping offset operating losses.
Investment portfolio remains liquid: Roivant sold or received maturities of $568.2 million of investments during Q1 while still reporting positive investing cash flow of $281.3 million.
Revenue remains limited and volatile: Quarterly revenue has generally stayed in the low-single-digit millions recently, making expense management and future product commercialization especially important.
Reported earnings are affected by unusual items: Q4 2025 included a $770.2 million favorable special item, which contributed to reported net income of $355.7 million. The return to a $290.6 million loss in Q1 2026 highlights the volatility of nonrecurring gains and charges.
Operating losses remain substantial: Q1 2026 operating expenses totaled $367.4 million against just $1.4 million of revenue, resulting in a $366.0 million operating loss.
Operating cash burn worsened: Cash flow from operating activities deteriorated to negative $270.5 million in Q1 2026 from negative $163.8 million in Q4 2025.
Accumulated losses are growing: Retained earnings declined to negative $900.4 million in Q1 2026 from negative $695.0 million in Q3 2025 and positive $671.5 million in Q1 2024.
Share count remains a dilution risk: Despite continued repurchases, weighted-average basic shares rose to approximately 720.8 million in Q1 2026 from 693.9 million in Q4 2025, which can reduce per-share benefits for existing investors.

11/14/26 01:58 AM ETAI Generated. May Contain Errors.

Roivant Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Roivant Sciences' financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Roivant Sciences' net income appears to be on an upward trend, with a most recent value of -$397.91 million in 2025, rising from -$900.23 million in 2020. The previous period was -$356.73 million in 2024. View Roivant Sciences' forecast to see where analysts expect Roivant Sciences to go next.

Roivant Sciences' total operating income in 2025 was -$515.07 million, based on the following breakdown:

Total Gross Profit: $8.26 million
Total Operating Expenses: $523.33 million

Over the last 5 years, Roivant Sciences' total revenue changed from $23.80 million in 2020 to $8.26 million in 2025, a change of -65.3%.

In the past 13 quarters, Roivant Sciences' cash and equivalents has ranged from $1.24 billion in Q2 2025 to $6.67 billion in Q3 2023, and is currently $1.64 billion as of their latest financial filing in Q2 2026.

Roivant Sciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2020.

Over the last 5 years, Roivant Sciences' book value per share changed from 2.85 in 2020 to 6.33 in 2025, a change of 121.7%.

Related Companies

Financial statements for NASDAQ:ROIV last updated on 11/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Financials

Financials Breakdown Chart

Key Financial Trends

Roivant Sciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Financials

Annual Income Statements for Roivant Sciences

Quarterly Income Statements for Roivant Sciences

Annual Cash Flow Statements for Roivant Sciences

Quarterly Cash Flow Statements for Roivant Sciences

Annual Balance Sheets for Roivant Sciences

Quarterly Balance Sheets for Roivant Sciences

Annual Metrics And Ratios for Roivant Sciences

Quarterly Metrics And Ratios for Roivant Sciences

Financials Breakdown Chart

Key Financial Trends

Roivant Sciences Financials - Frequently Asked Questions

When does Roivant Sciences' fiscal year end?

How has Roivant Sciences' net income changed over the last 5 years?

What is Roivant Sciences' operating income?

How has Roivant Sciences' revenue changed over the last 5 years?

How much cash does Roivant Sciences have?

How much debt does Roivant Sciences have?

How has Roivant Sciences' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools